Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Comparison of End-Tidal, Arterial, Venous, and Transcutaneous PCO2.

Fujimoto S, Suzuki M, Sakamoto K, Ibusuki R, Tamura K, Shiozawa A, Ishii S, Iikura M, Izumi S, Sugiyama H.

Respir Care. 2019 Oct;64(10):1208-1214. doi: 10.4187/respcare.06094. Epub 2019 Jul 23.

PMID:
31337742
2.

Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression.

Wang ST, Anderson IM, Mitchell D, Johnson SJ, Shiozawa A.

Clinicoecon Outcomes Res. 2019 Mar 14;11:257-270. doi: 10.2147/CEOR.S181718. eCollection 2019.

3.

Hyperactivation of proprioceptors induces microglia-mediated long-lasting pain in a rat model of chronic fatigue syndrome.

Yasui M, Menjyo Y, Tokizane K, Shiozawa A, Tsuda M, Inoue K, Kiyama H.

J Neuroinflammation. 2019 Mar 30;16(1):67. doi: 10.1186/s12974-019-1456-x.

4.

Postoperative Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: Impact of High-Dose Corticosteroid Nasal Spray.

Ikeda K, Ito S, Hibiya R, Homma H, Ono N, Okada H, Kidokoro Y, Shiozawa A, Kusunoki T.

Int Arch Otorhinolaryngol. 2019 Jan;23(1):101-103. doi: 10.1055/s-0038-1668515. Epub 2018 Oct 24.

5.

Effectiveness of clarithromycin in patients with yellow nail syndrome.

Matsubayashi S, Suzuki M, Suzuki T, Shiozawa A, Kobayashi K, Ishii S, Iikura M, Izumi S, Kudo K, Sugiyama H.

BMC Pulm Med. 2018 Aug 15;18(1):138. doi: 10.1186/s12890-018-0707-4.

6.

Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data.

Ogino M, Shiozawa A, Ota H, Okamoto S, Hiroi S, Kawachi I.

Neurodegener Dis Manag. 2018 Apr;8(2):97-103. doi: 10.2217/nmt-2017-0047. Epub 2018 Apr 25.

7.

Massive Hemoptysis with a Fungus Ball-like Shadow in an Old Tuberculosis Cavity That Was Shown to Be a Clot by Bronchoscopy.

Kawamoto H, Suzuki M, Shiozawa A, Miyawaki E, Yamamoto S, Kobayashi K, Takasaki J, Takeda Y, Hojo M, Sugiyama H.

Intern Med. 2018 Feb 1;57(3):377-381. doi: 10.2169/internalmedicine.8967-17. Epub 2017 Nov 1.

8.

Early-onset, Severe Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension that was Likely Induced by Toluene Exposure.

Kobayashi K, Suzuki M, Yamamoto S, Ueno K, Miyawaki E, Takazawa I, Shiozawa A, Sato T, Hojo M, Sugiyama H.

Intern Med. 2017 Sep 1;56(17):2329-2334. doi: 10.2169/internalmedicine.8077-16. Epub 2017 Aug 10.

9.

Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.

Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK.

J Rheumatol. 2017 Mar;44(3):388-396. doi: 10.3899/jrheum.160452. Epub 2017 Feb 1. Review.

PMID:
28148699
10.

Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.

Shiozawa A, Buysman EK, Korrer S.

Curr Med Res Opin. 2017 Jan;33(1):117-124. Epub 2016 Oct 21.

PMID:
27659103
11.

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A.

Clin Ther. 2016 Jul;38(7):1710-25. doi: 10.1016/j.clinthera.2016.05.007. Epub 2016 Jun 3.

PMID:
27269247
12.

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

Altan A, Shiozawa A, Bancroft T, Singh JA.

J Clin Rheumatol. 2015 Dec;21(8):411-8. doi: 10.1097/RHU.0000000000000322.

13.

Febuxostat in the management of gout: a cost-effectiveness analysis.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A.

J Med Econ. 2016;19(3):265-76. doi: 10.3111/13696998.2015.1116990. Epub 2015 Nov 23.

PMID:
26535593
14.

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Singh JA, Akhras KS, Shiozawa A.

Arthritis Res Ther. 2015 Sep 2;17:236. doi: 10.1186/s13075-015-0752-9. No abstract available.

15.

Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting.

Khanna PP, Shiozawa A, Walker V, Bancroft T, Essoi B, Akhras KS, Khanna D.

Patient Prefer Adherence. 2015 Jul 9;9:971-81. doi: 10.2147/PPA.S83700. eCollection 2015.

16.

Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis.

Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H.

BMJ Open. 2015 Jun 24;5(6):e007214. doi: 10.1136/bmjopen-2014-007214.

17.

Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.

Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

Curr Med Res Opin. 2015 Aug;31(8):1611-20. doi: 10.1185/03007995.2015.1062750. Epub 2015 Jul 17.

PMID:
26086788
18.

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Singh JA, Akhras KS, Shiozawa A.

Arthritis Res Ther. 2015 May 12;17:120. doi: 10.1186/s13075-015-0624-3. Erratum in: Arthritis Res Ther. 2015;17:236.

19.

Comparative analysis of cytokine release from epithelial cell cultures of the upper airway.

Shiozawa A, Miwa M, Ono N, Homma H, Hirotsu M, Ikeda K.

Rhinology. 2015 Jun;53(2):135-41. doi: 10.4193/Rhin14.078.

PMID:
25910474
20.

In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.

Yamaori S, Takami K, Shiozawa A, Sakuyama K, Matsuzawa N, Ohmori S.

Biol Pharm Bull. 2015;38(3):441-7. doi: 10.1248/bpb.b14-00711. Epub 2015 Jan 19.

21.

Physician adherence to ACR gout treatment guidelines: perception versus practice.

Oderda GM, Shiozawa A, Walsh M, Hess K, Brixner DI, Feehan M, Akhras K.

Postgrad Med. 2014 May;126(3):257-67. doi: 10.3810/pgm.2014.05.2774.

PMID:
24918810
22.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
23.

Fungal extracts detected in eosinophilic chronic rhinosinusitis induced cytokines from the nasal polyp cells.

Hirotsu M, Shiozawa A, Ono N, Miwa M, Kikuchi K, Ikeda K.

Laryngoscope. 2014 Sep;124(9):E347-53. doi: 10.1002/lary.24655. Epub 2014 Apr 4.

24.

Reduction in superoxide dismutase expression in the epithelial mucosa of eosinophilic chronic rhinosinusitis with nasal polyps.

Ono N, Kusunoki T, Miwa M, Hirotsu M, Shiozawa A, Ikeda K.

Int Arch Allergy Immunol. 2013;162(2):173-80. doi: 10.1159/000353122. Epub 2013 Jul 31.

PMID:
23921602
25.

Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil.

Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, Saitoh T, Murata J.

Laryngoscope. 2013 Nov;123(11):E1-9. doi: 10.1002/lary.24154. Epub 2013 May 13.

PMID:
23670893
26.
27.

An assessment of the impact of pregnancy on trauma mortality.

John PR, Shiozawa A, Haut ER, Efron DT, Haider A, Cornwell EE 3rd, Chang D.

Surgery. 2011 Jan;149(1):94-8. doi: 10.1016/j.surg.2010.04.019.

PMID:
21147307
28.

Cost of inpatient care and its association with hospital competition.

Chang DC, Shiozawa A, Nguyen LL, Chrouser KL, Perler BA, Freischlag JA, Colombani PM, Abdullah F.

J Am Coll Surg. 2011 Jan;212(1):12-9. doi: 10.1016/j.jamcollsurg.2010.09.014. Epub 2010 Nov 30.

PMID:
21123092
29.

An AP-1-like transcription factor, NAP-1, regulates expression of the glutathione S-transferase and NADH:flavin oxidoreductase genes in Neurospora crassa.

Takahashi M, Yamashita K, Shiozawa A, Ichiishi A, Fukumori F, Fujimura M.

Biosci Biotechnol Biochem. 2010;74(4):746-52. Epub 2010 Apr 7.

30.

ATF-1 transcription factor regulates the expression of ccg-1 and cat-1 genes in response to fludioxonil under OS-2 MAP kinase in Neurospora crassa.

Yamashita K, Shiozawa A, Watanabe S, Fukumori F, Kimura M, Fujimura M.

Fungal Genet Biol. 2008 Dec;45(12):1562-9. doi: 10.1016/j.fgb.2008.09.012. Epub 2008 Oct 10.

PMID:
18948219
31.

Involvement of OS-2 MAP kinase in regulation of the large-subunit catalases CAT-1 and CAT-3 in Neurospora crassa.

Yamashita K, Shiozawa A, Banno S, Fukumori F, Ichiishi A, Kimura M, Fujimura M.

Genes Genet Syst. 2007 Aug;82(4):301-10.

32.
33.

Highly stable gold(III) complex with a hydantoin ligand in alkaline media.

Oyaizu K, Ohtani Y, Shiozawa A, Sugawara K, Saito T, Yuasa M.

Inorg Chem. 2005 Oct 3;44(20):6915-7.

PMID:
16180847
34.

E-Cell 2: multi-platform E-Cell simulation system.

Takahashi K, Ishikawa N, Sadamoto Y, Sasamoto H, Ohta S, Shiozawa A, Miyoshi F, Naito Y, Nakayama Y, Tomita M.

Bioinformatics. 2003 Sep 1;19(13):1727-9.

PMID:
15593410
35.
37.

Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.

Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S.

Br J Cancer. 1999 Jul;80(10):1658-64.

38.

Effect of nonsteroidal anti-inflammatory drugs on lipid peroxidation by hydroxyl radical.

Tsujimoto Y, Saitoh K, Kashima M, Shiozawa A, Kozuka M, Hashizume H, Kimura K, Yamazaki M, Fujii A.

Gen Pharmacol. 1998 Sep;31(3):405-8.

PMID:
9703209
39.

Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins.

Tatee T, Narita A, Narita K, Izumi G, Takahira T, Sakurai M, Fujita A, Hosono M, Yamashita K, Enomoto K, Shiozawa A.

Chem Pharm Bull (Tokyo). 1996 Dec;44(12):2274-9.

PMID:
8996857
40.

[Bilateral renal cell carcinoma associated with von Hippel-Lindau disease].

Fukuda M, Satomi Y, Senga Y, Usuda K, Shiozawa A.

Hinyokika Kiyo. 1987 Jun;33(6):925-9. Japanese.

41.

Isoxazole derivatives as centrally acting muscle relaxants. I. Synthesis and activity of 5-(3-aminopropyl)amino-3-phenylisoxazole derivatives.

Tatee T, Kurashige S, Shiozawa A, Narita K, Takei M, Ito S, Miyazaki H, Yamanaka H, Mizugaki M, Sakamoto T, et al.

Chem Pharm Bull (Tokyo). 1986 Apr;34(4):1634-42. No abstract available.

PMID:
3719864
42.

Antivertigo agents. V. Quantitative structure-activity relationships of 6-[2-(4-aryl-1-piperazinyl)ethyl]-5,6,7,8-tetrahydro-1,6-naphthyridine s.

Shiozawa A, Kogo Y, Ichikawa Y, Komuro C, Ishikawa M, Kurashige S, Miyazaki H, Yamanaka H, Sakamoto T.

Chem Pharm Bull (Tokyo). 1985 Dec;33(12):5332-40. No abstract available.

PMID:
3833382
43.

Antivertigo agents. IV. Synthesis and antivertigo activity of 6-[omega-(4-aryl-1-piperazinyl)alkyl]-5,6,7,8-tetrahydro-1,6-naphth yridines.

Shiozawa A, Ichikawa Y, Komuro C, Ishikawa M, Furuta Y, Kurashige S, Miyazaki H, Yamanaka H, Sakamoto T.

Chem Pharm Bull (Tokyo). 1984 Oct;32(10):3981-93. No abstract available.

PMID:
6529796
44.

Antivertigo agents. III. Synthesis of 5,6,7,8-tetrahydro-1,6-naphthyridine methyl homologs.

Shiozawa A, Ichikawa Y, Komuro C, Kurashige S, Miyazaki H, Yamanaka H, Sakamoto T.

Chem Pharm Bull (Tokyo). 1984 Jul;32(7):2522-9. No abstract available.

PMID:
6499080
45.

Antivertigo agents. II. Structure-activity relationships of 6-substituted 5,6,7,8-tetrahydro-1,6-naphthyridines.

Shiozawa A, Ichikawa Y, Ishikawa M, Kogo Y, Kurashige S, Miyazaki H, Yamanaka H, Sakamoto T.

Chem Pharm Bull (Tokyo). 1984 Mar;32(3):995-1005. No abstract available.

PMID:
6744495
46.

Antivertigo agents. I. Structure-activity relationships of 2-(2-aminoethyl)pyridines.

Shiozawa A, Ichikawa Y, Komuro C, Idzu G, Ishikawa M, Kurashige S, Miyazaki H, Yamanaka H, Sakamoto T.

Chem Pharm Bull (Tokyo). 1984 Feb;32(2):553-63. No abstract available.

PMID:
6733806
47.

[Case of intralobar pulmonary sequestration--with special reference to angiographic findings].

Tanaka Y, Sasaki T, Shiozawa A, Obata Y, Takeichi M.

Rinsho Hoshasen. 1974 Apr;19(4):303-10. Japanese. No abstract available.

PMID:
4858669
48.

[Nursing study on the contamination of liquid medicines].

Kasuya M, Shiozawa A, Miura K, Yamamoto F.

Kangogaku Zasshi. 1965 Mar;29(3):91-5. Japanese. No abstract available.

PMID:
4954924

Supplemental Content

Loading ...
Support Center